BMO Capital Markets Analysts Give Pfizer (PFE) a $39.00 Price Target
Pfizer (NYSE:PFE) has been given a $39.00 target price by BMO Capital Markets in a research report issued on Friday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 6.97% from the company’s previous close.
PFE has been the subject of several other reports. ValuEngine raised Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, October 11th. Deutsche Bank set a $38.00 target price on Pfizer and gave the company a “buy” rating in a report on Wednesday, October 11th. Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $35.00 to $39.00 in a report on Wednesday, September 20th. Finally, Jefferies Group set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research note on Thursday, August 24th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $38.77.
Shares of Pfizer (NYSE:PFE) traded down $0.18 during mid-day trading on Friday, reaching $36.46. The company had a trading volume of 14,786,900 shares, compared to its average volume of 19,888,109. Pfizer has a fifty-two week low of $30.90 and a fifty-two week high of $36.89. The company has a market capitalization of $218,400.30, a PE ratio of 14.66, a P/E/G ratio of 2.59 and a beta of 1.01. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15.
Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The business had revenue of $13.17 billion during the quarter, compared to analysts’ expectations of $13.17 billion. During the same quarter last year, the business posted $0.61 earnings per share. The company’s quarterly revenue was up .9% on a year-over-year basis. sell-side analysts expect that Pfizer will post 2.59 EPS for the current year.
In other news, EVP Alexander R. Mackenzie sold 7,350 shares of the stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $35.65, for a total transaction of $262,027.50. Following the transaction, the executive vice president now owns 117,432 shares of the company’s stock, valued at approximately $4,186,450.80. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Alexander R. Mackenzie sold 14,700 shares of the stock in a transaction dated Wednesday, November 1st. The shares were sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The disclosure for this sale can be found here. Corporate insiders own 0.06% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Parametric Portfolio Associates LLC lifted its position in shares of Pfizer by 6.1% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 18,445,334 shares of the biopharmaceutical company’s stock worth $658,498,000 after acquiring an additional 1,062,191 shares during the period. Vista Private Wealth Partners. LLC bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $213,000. Sage Capital Advisors llc lifted its position in shares of Pfizer by 3.4% in the 3rd quarter. Sage Capital Advisors llc now owns 72,117 shares of the biopharmaceutical company’s stock worth $2,575,000 after acquiring an additional 2,382 shares during the period. Chicago Partners Investment Group LLC lifted its position in shares of Pfizer by 13.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 35,682 shares of the biopharmaceutical company’s stock worth $1,274,000 after acquiring an additional 4,287 shares during the period. Finally, Institutional & Family Asset Management LLC lifted its position in shares of Pfizer by 23.7% in the 3rd quarter. Institutional & Family Asset Management LLC now owns 17,890 shares of the biopharmaceutical company’s stock worth $639,000 after acquiring an additional 3,429 shares during the period. 69.89% of the stock is currently owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.